Health tech

Story hook

On 16 January 2021, at 9:38 AM, a 34-year-old sanitation worker named Manish Kumar rolled up the sleeve of his hospital scrubs at AIIMS Delhi and became the first Indian to receive a COVID-19 vaccine. The shot was Covishield — manufactured at the Serum Institute of India in Pune under licence from the University of Oxford and AstraZeneca. It was an adenovirus vector vaccine, not the mRNA type that Pfizer and Moderna were rolling out in the West.

That choice was deliberate. India had no mRNA vaccine of its own. It had no domestic lipid nanoparticle (LNP) capability — the fatty bubbles that wrap mRNA so it can enter human cells. It had no facility that could keep doses at –70 °C. So India bet on what it could build: an inactivated virus vaccine (Covaxin, Bharat Biotech) and a viral vector vaccine (Covishield, SII), both of which the country had decades of experience manufacturing at giant scale.

Behind Manish's jab was something else: a mobile-phone-linked, Aadhaar-anchored, real-time appointment and certificate system called Co-WIN that the rest of the world watched with astonishment. By August 2023, Co-WIN had recorded 2.2 billion doses, generated 2.2 billion QR-coded certificates, and become the digital backbone of what is, by far, the largest single- disease vaccination drive in human history.

Why this matters for UPSC

Health-tech and Co-WIN are now a recurring S&T anchor in UPSC. Prelims questions on COVID vaccine platforms (mRNA vs viral vector vs inactivated), on Co-WIN architecture, on the Ayushman Bharat Digital Mission (ABDM) and Ayushman Bharat Health Account (ABHA), on mRNA-platform indigenisation (Gemcovac-OM, Gemcovac-19), and on DPI export are now mainstream. Mains overlap with health policy (GS-II), digital governance (GS-II), and pharma economy (GS-III).